Cure8 research brief
Cure8 research brief
The paper suggests a molecular link (RHBDF2–ADAM17–TNFα) between ulcerative colitis and blood–brain barrier disruption, which could explain some neurological comorbidities of UC and identify targets for future therapies.
Researchers on IBD and neuroinflammation; clinicians managing UC patients with neurological symptoms; patients interested in IBD-related brain risks
Researchers combined multi-cohort human transcriptome meta-analysis with single-cell RNA-seq and genetic causal inference (SMR) to find genes up-regulated in both UC colon tissue and models of BBB disruption. RHBDF2 emerged as a shared, cell-type-specific mediator (epithelial cells in colon; endothelial cells at the BBB) linked to ADAM17 and TNFα signaling.
In mice with DSS-induced colitis, preventive treatment with the ADAM17 inhibitor GW280264X reduced intestinal inflammation, lowered brain markers (Rhbdf2, Adam17, Tnfα), and decreased Evans blue dye leakage into the brain, supporting a functional role for this axis in BBB permeability.
These results are integrative and preclinical: they combine human genomics and experimental validation but do not by themselves establish an effective therapy for people with UC.
Findings combine human genomic analyses and mouse experiments (DSS colitis + ADAM17 inhibitor) and should be considered preliminary regarding therapeutic implications.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.